|
1
|
Randi G, Malvezzi M, Levi F, Ferlay J,
Negri E, Franceschi S and La Vecchia C: Epidemiology of biliary
tract cancers: An update. Ann Oncol. 20:146–159. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hezel AF and Zhu AX: Systemic therapy for
biliary tract cancers. Oncologist. 13:415–423. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Donohue JH, Stewart AK and Menck HR: The
national cancer data base report on carcinoma of the gallbladder,
1989–1995. Cancer. 83:2618–2628. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eckel F and Schmid RM: Chemotherapy in
advanced biliary tract carcinoma: A pooled analysis of clinical
trials. Br J Cancer. 96:896–902. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Watanabe Y, Goto H, Hirooka Y, Itoh A,
Taki T, Hayakawa S, Hayakawa T, Naitoh Y, Ohhashi K, Yamao K and
Furukawa T: Transpapillary biopsy in gallbladder disease.
Gastrointest Endosc. 51:76–79. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duffy A, Capanu M, Abou-Alfa GK, Huitzil
D, Jarnagin W, Fong Y, D'Angelica M, Dematteo RP, Blumgart LH and
O'Reilly EM: Gallbladder cancer (GBC): 10-year experience at
memorial Sloan-Kettering cancer centre (MSKCC). J Surg Oncol.
98:485–489. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary
Cancers (version 2, 2016). https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdfAccessed.
July 6–2016
|
|
8
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging HandbookFrom the AJCC
Cancer Staging Manual. 7th. Springer; New York: 2010
|
|
9
|
Lazcano-Ponce EC, Miquel JF, Muñoz N,
Herrero R, Ferrecio C, Wistuba II, de Ruiz P Alonso, Urista G
Aristi and Nervi F: Epidemiology and molecular pathology of
gallbladder cancer. CA Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sheth S, Bedford A and Chopra S: Primary
gallbladder cancer: Recognition of risk factors and the role of
prophylactic cholecystectomy. Am J Gastroenterol. 95:1402–1410.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bosman FT, Carneiro F, Hruban RH and
Threise ND: WHO Classification of Tumours of the Digestive System.
4th. IARC Press; Lyon: 2010
|
|
12
|
Shimizu T, Arima Y, Yokomuro S, Yoshida H,
Mamada Y, Nomura T, Taniai N, Aimoto T, Nakamura Y, Mizuguchi Y, et
al: Incidental gallbladder cancer diagnosed during and after
laparoscopic cholecystectomy. J Nippon Med Sch. 73:136–140. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gebbia N, Verderame F, Di Leo R,
Santangelo D, Cicero G, Valerio MR, Arcara C, Badalamenti G,
Fulfaro F and Carreca I: A phase II study of oxaliplatin (O) and
gemcitabine (G) first line chemotherapy in patients with advanced
biliary tract cancers. J Clin Oncol. 23(suppl): abstract 4132.
2005.
|
|
14
|
Kuriyama H, Kawana K, Taniguchi R, Jono F,
Sakai E, Okubo H, Suzuki H, Kobayashi S, Murata Y, Inamori M, et
al: Single-agent gemcitabine in elderly patients with unresectable
biliary tract cancer. Hepatogastroenterology. 58:26–30.
2011.PubMed/NCBI
|
|
15
|
Ueno H, Okusaka T, Ikeda M, Takezako Y and
Morizane C: Phase II study of S-1 in patients with advanced biliary
tract cancer. Br J Cancer. 91:1769–1774. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harder J, Riecken B, Kummer O, Lohrmann C,
Otto F, Usadel H, Geissler M, Opitz O and Henss H: Outpatient
chemotherapy with gemcitabine and oxaliplatin in patients with
biliary tract cancer. Br J Cancer. 95:848–852. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Williams KJ, Picus J, Trinkhaus K,
Fournier CC, Suresh R, James JS and Tan BR: Gemcitabine with
carboplatin for advanced biliary tract cancers: A phase II single
institution study. HPB (Oxford). 12:418–426. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Petera J, Kasaová L, Paluska P, Sirák I,
Jansa J, Macingová Z, Dvorák J and Soumarova R: Intensity-modulated
radiotherapy in the treatment of subhepatic carcinomas.
Hepatogastroenterology. 58:331–335. 2011.PubMed/NCBI
|
|
19
|
Beltrán M Bonet, Roth AD, Mentha G and
Allal AS: Adjuvant radio-chemotherapy for extrahepatic biliary
tract cancers. BMC Cancer. 11:2672011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoshikawa D, Ojima H, Iwasaki M, Hiraoka
N, Kosuge T, Kasai S, Hirohashi S and Shibata T:
Clinicopathological and prognostic significance of EGFR, VEGF, and
HER2 expression in cholangiocarcinoma. Br J Cancer. 98:418–425.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gruenberger B, Schueller J, Heubrandtner
U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S and
Gruenberger T: Cetuximab, gemcitabine, and oxaliplatin in patients
with unresectable advanced or metastatic biliary tract cancer: A
phase 2 study. Lancet Oncol. 11:1142–1148. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang PY, Cheng MF, Lee HS, Hsieh CB and
Yao NS: Preliminary experience of cetuximab in the treatment of
advanced-stage biliary tract cancer. Onkologie. 33:45–47. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zitvogel L, Apetoh L, Ghiringhelli F,
André F, Tesniere A and Kroemer G: The anticancer immune response:
Indispensable for therapeutic success? J Clin Invest.
118:1991–2001. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Correale P, Cusi MG, Tsang KY, Del Vecchio
MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini
C, et al: Chemo-immunotherapy of metastatic colorectal carcinoma
with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte
macrophage colony-stimulating factor and interleukin-2 induces
strong immunologic and antitumor activity in metastatic colon
cancer patients. J Clin Oncol. 23:8950–8958. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O'Day SJ, Atkins MB, Boasberg P, Wang HJ,
Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh
EM and Weber JS: Phase II multicenter trial of maintenance
biotherapy after induction concurrent biochemotherapy for patients
with metastatic melanoma. J Clin Oncol. 27:6207–6212. 2009.
View Article : Google Scholar : PubMed/NCBI
|
